Just as plan sponsors begin to gain their footing on GLP-1 management strategies, another emerging category is quietly advancing through the pipeline: hair loss treatment.

Historically, treatment options for pattern hair loss have limited choices at a modest cost ranging from topical minoxidil (Rogaine®), to oral finasteride, and various off-label therapies. However, a new generation of non-specialty (VDPHL01) and specialty (PP405) medications are being developed that could significantly improve outcomes for both men and women experiencing hair loss.

Why Should This Concern Plan Sponsors?

Pattern hair loss affects approximately 80 million adults in the United States¹, creating substantial utilization potential if these therapies receive FDA approval and gain market acceptance.

None of the medications discussed below are FDA-approved at this time, but they represent two pipeline products that could have meaningful clinical and financial implications for employer-sponsored health plans.

1. VDPHL01: Minoxidil 2.0

VDPHL01 is an oral, non-hormonal hair loss pill used to treat men and women.  The extended-release oral minoxidil tablet delivers hair regrowth benefits while avoiding the heart-related risks tied to immediate-release oral minoxidil. Phase 2/3 Study results released April 27, 2026 show strong efficacy signals, with robust hair growth seen in both once-daily and twice-daily dosing. Phase 3 studies are still being conducted.

If approved, VDPHL01 will become the first FDA-approved oral pill in nearly 30 years for treatment of pattern hair loss.²

VDPHL01 Estimated Market Availability: Late 2027 to early 2028. (pending successful completion of clinical trials and regulatory review).

Potential Financial Impact: Moderate to High

Plan sponsors should pay close attention because:

• Oral medications are easy to prescribe and administer.
• Clinical studies suggest meaningful hair regrowth benefits.
• The eligible population includes both men and women.
• Even a modest annual treatment cost can generate significant plan spend when multiplied across a large member population.

2. PP405: A Potentially Disruptive Stem Cell-Based Approach

PP405 represents a very different approach to treating hair loss. Rather than targeting hormones or improving blood flow, PP405 is designed to reactivate dormant hair follicle stem cells and stimulate new growth at the cellular level. The therapy is being developed for both men and women with pattern hair loss.

In a Phase 2 study, PP405 demonstrated a favorable safety profile with no treatment-related systemic adverse events reported. Phase 3 trials are expected to begin, although the product remains several years away from potential commercialization.³

Consumer excitement around PP405 has been substantial because it represents one of the first therapies seeking to regenerate hair growth by reactivating dormant follicles rather than slowing the progression of hair loss.

PP405 Estimated Market Availability: To be determined. The product remains in clinical development.

Potential Financial Impact: Moderate to High

From a pharmacy benefit perspective, this may be the more disruptive product.

If larger clinical trials confirm strong efficacy:

• Demand could be significant.
• Use could extend across a broad population of men and women.
• Treatment may begin earlier in the disease progression process.
• Specialty-drug pricing could place additional pressure on pharmacy budgets.
• Physicians may view treatment as preventative rather than purely restorative.

How to Begin Assessing Your Rx Benefits Risk for Hair Loss Coverage

12-24 months before launch:

1. Assess whether your current Rx and/or Medical benefits provide for hair loss treatments.
2. For Benecard plan sponsors, have your brokers contact Benecard for the number of eligible members and their utilization based on any hair loss treatment usage from the most recent 12 months.
3. Rethink Plan Design and Utilization Management Options for Hair Loss Category:
   1. Exclude
   2. Prior Authorization
   3. Step Therapy
   4. Member Cost Sharing

Although VDPHL01 and PP405 remain investigational therapies, both highlight a broader shift toward innovative treatments for highly prevalent lifestyle and quality-of-life conditions. For plan sponsors, the challenge will be balancing member access with responsible drug management tools in place prior to these drugs entering the marketplace.

Getting ahead of these therapies now allows organizations to thoughtfully design coverage and drug management strategies before high demand and additional cost increases arrive. To talk pharmacy benefit strategy, contact your Benecard Representative at talktous@benecard.com.

1. https://medlineplus.gov/genetics/condition/androgenetic-alopecia/#frequency
2. Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss | Mon, 04/27/2026 – 07:00
3. https://www.dermatologytimes.com/view/reactivating-the-follicle-pp405-moves-toward-late-stage-trials-for-alopecia